Автор: KUM
создано: 11.03.2009 20:28
CLINICAL MANAGEMENT USING LOW-MOLECULAR-WEIGHT HEPARIN (LMWH) IN PREGNANT WOMEN WITH THROMBOPHILIA, THROMBOEMBOLIC DISEASE (DVT) OR THROMBOPHILIA-RELATED MATERNOPLACENTAL SYNDROME: EXPERIENCE IN ONE CENTER
Abstract number: P-W-587
Santamaría1 A., Vila2 J., Marco2 A., Mateo2 J., Simó3 M., Fontcuberta2 J.
11Hematology, Hospital de la santa Creu i Sant Pau, Barcelona, Spain 22Hematology 33Ginecology, Hospital de la santa Creu i Sant Pau, Barcelona, SPAIN
How-to-cite Santamaría A, Vila J, Marco A, Mateo J, Simó M, Fontcuberta J. CLINICAL MANAGEMENT USING LOW-MOLECULAR-WEIGHT HEPARIN (LMWH) IN PREGNANT WOMEN WITH THROMBOPHILIA, THROMBOEMBOLIC DISEASE (DVT) OR THROMBOPHILIA-RELATED MATERNOPLACENTAL SYNDROME: EXPERIENCE IN ONE CENTER. J Thromb Haemost 2007; 5 Supplement 2: P-W-587
Abstract
Introduction: A better understanding of the use of anticoagulation in pregnancy is essential for the prevention and treatment of DVT and thrombophilia-related maternoplacental syndrome (MPS).
In our center, we have performed an observational study to evaluate complications of pregnancy and pregnancy outcomes in women under prophylactic and therapeutical treatment with LMWH.
Methods: Fifty-seven pregnant women with median age of 34 years, were managed with LMWH. They were divided into two subgroups. In the thromboprophilaxis group, 47 women were included, 12 women with no history of thrombosis and thrombophilia, 11 women with history of MPS and thrombophilia, 3 women with SMP and 21 with history of TVD (13 women had thrombophilia, 2 had history of MPS, 4 women had MPS and thrombophilia and 2 women had history of idiopathic TVD). In the treatment group (n=10), 3 women had DVT and thrombophilia, 4 had idiopathic DVT, 2 had DVT and thrombophilia and 1 women had history of MPS and thrombophilia.
Results: In total, 57 pregnant women were treated with LMWH (bemiparin (Hibor®) or tinzaparin (Innohep®)). Among them, 29 were treated with thromboprophylactic dosages and 28 were treated with therapeutic dosages. Only 7 women presented clinical complications during pregnancy but not attributed to the LMWH treatment. Only one developed DVT and another one had a pregnancy loss.
Conclusions: LMWH treatment during pregnancy was safe and resulted in improved gestacional outcome. Given the lack of a common clinical practice, there is a need to establish multidisciplinar Units to recommend the best management of pregnant women with thrombophilia-related disorders.
To cite this abstract use the following format:
Journal of Thrombosis and Haemostasis 2007; Volume 5, Supplement 2: abstract number
Session Details
Date: 01/08/2007
Time: 00:00-00:00
Session name: XXIst ISTH Congress
Subject:
Location: Oxford, UK
Presentation type:
|
гепарины 